Hereditary Hemorrhagic Telangiectasia, Gene Mutation Panel
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant vascular disorder leading to telangiectases and arteriovenous malformations of skin, mucosa, and viscera. Arteriovenous malformations (AVMs) are direct connections between arteries and veins that lack intervening capillary beds. The clinical manifestations include spontaneous and recurrent nosebleeds (epistaxis) and telangiectases (small AVMs) on the lips, tongue, buccal mucosa, face, chest, and fingers. Large AVMs in the lungs, liver, GI tract and central nervous system may cause symptoms due to mass effect, bleeding or shunting. Patients may experience transient ischemic attacks, embolic strokes, cerebral hemorrhage, seizures, paralysis, heart failure, hemoptysis, hemothorax, and GI bleeding. The incidence of HHT is between 1 in 5,000 and 1 in 10,000 people and affects men, and women of all ethnic groups.
To date all of the mutations associated with HHT occur in genes that encode proteins involved in the transforming growth factor beta (TGFß) signaling pathway, including ACVRL1, ENG, GDF2 and SMAD4. While HHT patients may demonstrate any or all of the clinical features of the disorder there are some differences depending on the gene mutation involved. Patients with mutations in the ENG gene that encodes for endoglin have HHT Type 1 which has an earlier age of onset and higher incidence of lung and CNS AVMs. HHT Type 2 is caused by mutations in ACVRL1 and patients tend to have a higher incidence of hepatic AVMs, and pulmonary hypertension. Patients with mutations in SMAD4 may have features of juvenile polyposis syndrome (JPS), HHT or both.
- Diagnostic confirmation of HHT in symptomatic individuals
- Carrier screening in family members of an affected patient
- For the prenatal genetic testing in at risk pregnancies
- For pre-implantation genetic diagnosis of HHT
- To assist with prognosis, clinical management and surveillance for disease features based on the genetic variant involved.
Negative for mutations or pathogenic variants in a tested genes
Whole blood (EDTA).
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Frozen: Unacceptable
- Genet Med. 2011;13: 607-16. [PMID: 21546842]
- J Thromb Haemost. 2010;8: 1447-56. [PMID: 20345718]
- Ir J Med Sci. 2009;178: 135-46. [PMID: 18923886]
- Eur J Hum Genet. 2009;17: 860-71. [PMID: 19337313]
- Gastroenterol Nurs. 2007;30: 293-9; quiz 300-1. [PMID: 17724405]
- Genetics Home Reference. Available at: https://ghr.nlm.nih.gov/condition/hereditary-hemorrhagic-telangiectasia#
- GeneReviews® [Internet]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1351/
- Genetics Home Reference. Available at: https://ghr.nlm.nih.gov/gene/ACVRL1#
- Genetics Home Reference. Available at: https://ghr.nlm.nih.gov/gene/ENG#